NasdaqGS:ABOSBiotechs
Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative?
Acumen Pharmaceuticals recently reported that its Chief Medical Officer and Chief Financial Officer sold shares under pre-arranged trading plans to cover tax obligations from vested restricted stock units, while the company dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug in Alzheimer’s disease.
The combination of extending sabirnetug treatment for an additional 52 weeks and sharing fresh clinical research and recruitment insights...